NCT07105566Not yet recruiting
Triosephosphate Isomerase Level in Relation to Rheumatoid Aerthritis Activity and Structural Damage
Serum Triosephosphate Isomerase Level in Pateints With Rheumatoid Arthritis : Relation to Disease Activity and Structural Damage
Source: ClinicalTrials.gov · Last updated 6 Aug 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
1. Assess the serum level of TPI in patients with RA compared to healthy controls. 2. Correlate serum level of TPI and disease activity. 3. Correlation of serum TPI level with US7 damage index
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 70 (estimated)
- First submitted
- 16 Jul 2025
- Start date
- Sept 2025
- Primary completion date
- Sept 2027
- Lead sponsor
- Assiut University
- Diseases
- Rheumatoid arthritis
- NCT number
- NCT07105566
What you commit to
- Study type: Observational
- Planned participants: 70
- From Sept 2025 to the primary completion date, Sept 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Individuals with uncontrolled chronic diseases such as hypertension , diabetes, heart disease, liver or kidney disease, other autoimmune disorders and tumors.
- Rheumatologic diseases other than RA
Other
- Pregnant women.
Who the study is looking for
- \- Adult patients with RA who fulfill 2010 ACR/EULAR classification criteria
Age in the registry: 18 years to 50 years · Sex: All
This page is information, not medical advice. Discuss any trial with your doctor.